Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-CZP PET Imaging in Rheumatoid Arthritis
NCT03546335Phase 1Suspended
- Start
- Oct 2018
- Primary completion
- Mar 2029
- Modality
- Antibody Fragments, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-DFO-CZP in rheumatoid arthritis (RA) (4 arms). Primary endpoint: Uptake of 89Zr-DFO-CZP taken up in symptomatic versus asymptomatic joints at 2 years. Started Oct 2018; status: suspended.
02
Drugs
89Zr-DFO-CZP
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03546335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546335.